Overview

Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma

Status:
Terminated

Trial end date:
2019-01-28

Target enrollment:

Participant gender:

Summary

This study involves receiving blinatumomab after high-dose melphalan and ASCT for multiple myeloma. The main purpose of this study is to: - To determine whether blinatumomab is safe and feasible to administer after ASCT in patients with advanced multiple myeloma. - To assess how long multiple myeloma remains under control when blinatumomab is administered after second ASCT.

Phase:

Early Phase 1

Details

Lead Sponsor:

Abramson Cancer Center of the University of Pennsylvania

Treatments:

Antibodies, Bispecific
Blinatumomab